Articles
Vaccination with the mRNA-1273 vaccine (Moderna) appears safe in patients with solid tumors receiving immunotherapy, chemotherapy, or chemoimmunotherapy. Read More ›
At “The Pharma Pipeline” Roundtable during the 3rd Annual CCA Summit, experts from several pharmaceutical companies discussed recent and upcoming drugs in development for cholangiocarcinoma (CCA), emphasizing drug safety and a focus on patients. Read More ›
Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct)DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit. Read More ›
According to data from a European registry, approximately 1 in 6 patients with cancer who recovered from COVID-19 infection experienced long-term sequelae (ie, “long-haul” COVID-19), placing them at increased risk for death or discontinuation of anticancer treatment. Read More ›
The benefits of next-generation sequencing, liquid biopsy, the need for integration of local and systemic therapies, advanced intraductal interventions, and advanced radiotherapy technologies in biliary tract cancers were addressed in Session VII, “Interventional Oncology and Locoregional Therapy,” at the 3rd Annual CCA Summit. Read More ›
By William King
Treatment with the investigational agent mosunetuzumab (RG7828) as monotherapy induced deep remissions in patients with relapsed/refractory follicular lymphoma, according to results of a recent trial presented at the ASH 2021 Annual Meeting and Exposition. Read More ›
By William King
At the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021, a panel of experts, moderated by Michael Reff, RPh, MBA, Founder and Executive Director, National Community Oncology Dispensing Association (NCODA), Cazenovia, NY, discussed the current and future state of Medically Integrated Pharmacy (MIP) and the benefits of this approach in oncology. Read More ›
Adagrasib (MRTX849), an inhibitor of the KRASG12C mutation, showed promising activity as monotherapy and in combination with cetuximab (Erbitux) in patients with metastatic colorectal cancer (CRC) in the phase 1/2 KRYSTAL-1 trial. Read More ›
The ongoing COVID-19 pandemic has brought to the forefront the importance of advance care planning. Read More ›
In the January issue of The Oncology Pharmacist (TOP), we feature the latest news and updates relevant to pharmacy professionals working in the field of oncology. Read More ›